Investigating the Therapeutic Effect of Lota Carrageenan in Allergic and Non-Allergic Rhinitis

Document Type : Original Article


1 Department of Allergy and Immunology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Hematology and Blood Banking Department, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.


Allergic and non-allergic rhinitis are chronic upper airway inflammatory diseases. Iota carrageenan is an herbal extract of red algae used as a prophylactic treatment for rhinitis in the common cold and other viral infections. This study was designed to evaluate the clinical efficacy of Iota carrageenan in the treatment of allergic and non-allergic rhinitis.
 Materials and Methods:
60 patients with allergic and non-allergic rhinitis clinical symptoms were randomly divided into carrageenan and placebo (control) groups. The Standard Sino-Nasal Outcome Questionnaire 22 (SNOT-22) and Rhino Juniper Mini Conjunctivitis Quality of Life Questionnaire (Mini-RQLQ) were completed for each patient before and after receiving the drug. Smear of nasal secretions and rhinomanometry were also performed for all studied participants.
The mean score of SNOT-22 in the study group was 43.3 and 23.7 in the first and fourth weeks after therapy. The mean score of Mini RQLQ was 36.3 and 19.3 at the same time points (P< 0.001). SNOT-22 (P= 0.002) and Mini RQLQ (P= 0.005) scores showed a statistically significant decrease in the study group compared to the control group. The decrease in the eosinophil count and rhinomanometry results following treatment in both groups was statistically insignificant.
Our findings showed a positive effect for carrageenan over placebo in the management of both non-allergic and allergic rhinitis in symptom control. However, non-allergic rhinitis patients’ symptoms may improve better with this drug.


Main Subjects

  1. Agnihotri NT, McGrath KG, editors. Allergic and nonallergic rhinitis. Allergy Asthma Proc; 2019;40(6);376.
  2. Kouzegaran S, Zamani MA, Faridhosseini R, Rafatpanah H, Rezaee A, Yousefzadeh H, et al. Immunotherapy in Allergic Rhinitis: It's Effect on the Immune System and Clinical Symptoms. Open Access Maced J Med Sci. 2018;6:1248-52.
  3. Gelardi M. MaSelli Del giuDice a, Fiorella Ml, Fiorel-la r, ruSSo c, Soleti P, Di gioaccHino M, ciPranDi g. Non-allergic rhinitis with eosinophils and mast cells constitutes a new severe nasal disorder. Int J Immunopathol Pharmacol. 2008; 21: 325-31.
  4. Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013;160:393-400.
  5. Tehrani H, Faridhosseni R, Jabbari Azad F, Zamani MA, Rafatpanah H, Rezaee A, et al. Immunotherapy in allergic rhinitis: Its effect on the immune system and clinical symptoms. 3th International Congress of Immuonology, Asthma and Allergy and The First Symposium of Food and Drug Allergy; 2016 May3-6; Mashhad, Iran. 2016:33-33.
  6. Jabbariazad F, Faridhosseini R, Shirkani A, Tehrani H, Zamani M, Jafari M, et al., editors. The effect of subcutaneous immunotherapy for specific allergens on clinical symptoms and T regulatory and T helper cells cytokines in patients with allergic rhinitis. In Allergy. 2013; 68: 468-468.
  7. Weider DJ, Baker GL, Salvatoriello FW. Dental malocclusion and upper airway obstruction, an otolaryngologist's perspective. Int J Pediatr Otorhinolaryngol. 2003; 67:323-31.
  8. Hellgren J, Torén K. Nonallergic occupational rhinitis. Clin Allergy Immunol. 2007;19:241-8.
  9. Kaliner MA, Berger WE, Ratner PH, Siegel CJ. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2011; 106: S6-S11.
  10. Juel-Berg N, Darling P, Bolvig J, Foss-Skiftesvik MH, Halken S, Winther L, et al. Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: A systematic review and meta-analysis. Am J Rhinol. 2017; 31: e19-e28.
  11. Stiles J, Guptill-Yoran L, Moore GE, Pogranichniy RM. Effects of λ-carrageenan on in vitro replication of feline herpesvirus and on experimentally induced herpetic conjunctivitis in cats. Invest Ophthalmol Vis Sci. 2008;49: 1496-501.
  12. Shanmugam M, Mody K. Heparinoid-active sulphated polysaccharides from marine algae as potential blood anticoagulant agents. Curr Sci. 2000: 1672-83.
  13. Yuan H, Song J. Preparation, structural characterization and in vitro antitumor activity of kappa-carrageenan oligosaccharide fraction from Kappaphycus striatum. J Appl Phycol. 2005; 17:7-13.
  14. Yermak IM, Barabanova AO, Aminin DL, Davydova VN, Sokolova EV, Solov’eva TF, et al. Effects of structural peculiarities of carrageenans on their immunomodulatory and anticoagulant activities. Carbohydr Polym. 2012;87:713-20.
  15. Eccles R, Meier C, Jawad M, Weinmüllner R, Grassauer A, Prieschl-Grassauer E. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res. 2010; 11:1-10.
  16. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122: S1-S84.
  17. Ludwig M, Enzenhofer E, Schneider S, Rauch M, Bodenteich A, Neumann K, et al. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial. Respir Res. 2013;14:1-11.
  18. Leibbrandt A, Meier C, König-Schuster M, Weinmüllner R, Kalthoff D, Pflugfelder B, et al. Iota-carrageenan is a potent inhibitor of influenza A virus infection. PloS one. 2010; 5: e14320.
  19. Ratner PH, Paull BR, Findlay SR, Hampel Jr F, Martin B, Kral KM, et al. Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as beclomethasone dipropionate given twice daily. J Allergy Clin Immunol. 1992; 90:285-91.
  20. Van As A, Bronsky EA, Dockhorn RJ, Grossman J, Lumry W, Meltzer EO, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. J Allergy Clin Immunol. 1993;91:1146-54.
  21. Tran NP, Vickery J, Blaiss MS. Management of rhinitis: allergic and non-allergic. Allergy Asthma Immunol Res. 2011;3:148-56.